How BMS's all-oral HCV regimen lines up

A fixed-dose combination of daclatasvir, asunaprevir and BMS-791325 from Bristol-Myers Squibb Co. (NYSE:BMY) produced SVR12 rates of 92% in treatment-naive patients and 89% in treatment-experienced subjects in the Phase III UNITY-1 trial in non-cirrhotic HCV genotype 1 patients, according to abstracts released ahead of next month's American Association for the Study of Liver Diseases (AASLD) conference.

AASLD abstracts also were posted for BMS's Phase III UNITY-2 trial of the combo in HCV patients with compensated cirrhosis. SVR12 rates were 93% and 87% in treatment-naive and treatment-experienced patients. ...